These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31217295)

  • 21. The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.
    Chen J; Yang J; Cao P
    Mini Rev Med Chem; 2016; 16(16):1344-1358. PubMed ID: 27292784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
    Birendra KC; DiNardo CD
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
    Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS
    Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
    Ma T; Zou F; Pusch S; Xu Y; von Deimling A; Zha X
    J Med Chem; 2018 Oct; 61(20):8981-9003. PubMed ID: 29847930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
    Miller JJ; Shih HA; Andronesi OC; Cahill DP
    Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
    Mellinghoff IK; van den Bent MJ; Blumenthal DT; Touat M; Peters KB; Clarke J; Mendez J; Yust-Katz S; Welsh L; Mason WP; Ducray F; Umemura Y; Nabors B; Holdhoff M; Hottinger AF; Arakawa Y; Sepulveda JM; Wick W; Soffietti R; Perry JR; Giglio P; de la Fuente M; Maher EA; Schoenfeld S; Zhao D; Pandya SS; Steelman L; Hassan I; Wen PY; Cloughesy TF;
    N Engl J Med; 2023 Aug; 389(7):589-601. PubMed ID: 37272516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Headway against Brain Tumors with Molecular Targeting of IDH-Mutant Gliomas.
    Schiff D
    N Engl J Med; 2023 Aug; 389(7):653-654. PubMed ID: 37585632
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibition of mutant IDH1 in acute myeloid leukaemia.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638561
    [No Abstract]   [Full Text] [Related]  

  • 30. A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.
    Kats LM; Vervoort SJ; Cole R; Rogers AJ; Gregory GP; Vidacs E; Li J; Nagaraja R; Yen KE; Johnstone RW
    Leukemia; 2017 Jun; 31(6):1466-1470. PubMed ID: 28280273
    [No Abstract]   [Full Text] [Related]  

  • 31. IDH mutation in glioma: new insights and promises for the future.
    Turkalp Z; Karamchandani J; Das S
    JAMA Neurol; 2014 Oct; 71(10):1319-25. PubMed ID: 25155243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting IDH in Low-Grade Glioma.
    Claus EB; Verhaak RGW
    N Engl J Med; 2023 Aug; 389(7):655-659. PubMed ID: 37585633
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical development of IDH1 inhibitors for cancer therapy.
    Zarei M; Hue JJ; Hajihassani O; Graor HJ; Katayama ES; Loftus AW; Bajor D; Rothermel LD; Vaziri-Gohar A; Winter JM
    Cancer Treat Rev; 2022 Feb; 103():102334. PubMed ID: 34974243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Releasing the block: setting differentiation free with mutant IDH inhibitors.
    Pirozzi CJ; Reitman ZJ; Yan H
    Cancer Cell; 2013 May; 23(5):570-2. PubMed ID: 23680144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
    Lin J; Lu W; Caravella JA; Campbell AM; Diebold RB; Ericsson A; Fritzen E; Gustafson GR; Lancia DR; Shelekhin T; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Diep H; Kershaw M; Yao L; Kauffman G; Hubbs SE; Luke GP; Toms AV; Wang L; Bair KW; Barr KJ; Dinsmore C; Walker D; Ashwell S
    J Med Chem; 2019 Jul; 62(14):6575-6596. PubMed ID: 31199148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.
    Urban DJ; Martinez NJ; Davis MI; Brimacombe KR; Cheff DM; Lee TD; Henderson MJ; Titus SA; Pragani R; Rohde JM; Liu L; Fang Y; Karavadhi S; Shah P; Lee OW; Wang A; McIver A; Zheng H; Wang X; Xu X; Jadhav A; Simeonov A; Shen M; Boxer MB; Hall MD
    Sci Rep; 2017 Oct; 7(1):12758. PubMed ID: 28986582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities.
    Huang F; Tian T; Wu Y; Che J; Yang H; Dong X
    Mini Rev Med Chem; 2021; 21(9):1113-1122. PubMed ID: 33256576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
    Zheng Q; Tang S; Fu X; Chen Z; Ye Y; Lan X; Jiang L; Huang Y; Ding J; Geng M; Huang M; Wan H
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5262-5266. PubMed ID: 29079473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted rescue of cancer-associated IDH1 mutant activity using an engineered synthetic antibody.
    Rizk SS; Mukherjee S; Koide A; Koide S; Kossiakoff AA
    Sci Rep; 2017 Apr; 7(1):556. PubMed ID: 28373671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.